Prothena Corporation plc has announced that its partner Roche will advance the investigational drug prasinezumab into Phase III development for early-stage Parkinson's disease. This decision is based on data from the Phase IIb PADOVA study and ongoing open-label extensions from both the PADOVA and the Phase II PASADENA studies. Prasinezumab is an anti-alpha-synuclein antibody targeting a biological driver of Parkinson's disease progression. While the primary endpoint of time to confirmed motor progression did not achieve statistical significance, positive trends were noted, suggesting potential clinical benefits. The ongoing studies are evaluating the long-term safety and efficacy of prasinezumab in over 750 patients with early-stage Parkinson's disease. Further results from these studies will be presented as they become available.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。